{
  "name": "Masakazu Sekijima",
  "homepage": "http://www.cbi.c.titech.ac.jp",
  "status": "success",
  "content": "Èwåw@îñHw@@Ö¤º §åw@l@Èwåw îñHw@@îñHwn@Ö¤º §226-8501 ¡lsÎæ·Ãc¬4259-J3-23iJ318K1816ºj z[ o[ ¤àe ¤ÆÑ ²¤¶/åw@¶åW ¤¯¤ÉÂ¢Ä ßÌ¨mç¹ N Öui ¤ºÉÂ¢Ä @Ö¤ºÍA@BwKâX[p[Rs [eBOÆ¢¤æ¤ÈîñHwIÈè@ðp¢½nòâ¨¿EÞ¿ÌnoðÚwµÄ¢Ü·B±Ìæ¤ÈwâÌæðPCtH}eBNXâ}eAYCtH}eBNXÆ¾¢Ü·B fB[v[jOâ¶¬fAåKÍ¾êfÈÇÌ@BwKè@AX[p[Rs [^âo[`AeBÈÇAlXÈîñHwZpªPCtH}eBNXâ}eAYCtH}eBNXÉßçêÄ¢Ü·B á¦ÎARs [^ðp¢½nòÅÍfB[v[jOâªqV~ [Vðp¢Ä¾aÉÖW·é^pN¿iá¦ÎASARS-CoV-2Ì¡»É©©íé3CL Protease)Æ»¨Ì§Ì\\¢Ìîñðp¢ÄòóâÆÈé»¨ðTõ·éSBDDiStructure Based Drug DiscoveryjÌ¤ðs¤¾¯ÅÈ­AeJØTõâÏªI[gGR[_ðp¢Ä»¨ð¶¬·éè@ðJ­·é±ÆÅWI^pN¿É·éòçµ¢±êÜÅÉÈ©Á½»¨ð¶¬·é±ÆðÂ\\ÉµÄ«Ä¢Ü·BÜ½A±Ìæ¤È¤ðx¦éîñÈwÌîb¤ÉÂ¢ÄàsÁÄ¢Ü·B HÆåwÅÍ2024N4ÉTSUBAME4ÉAX[p[Rs [^ðXVµÜ·ªA±Ìæ¤ÈvZÂ«Í¤ðs¤ãÅ­ÝÉÈÁÄ¢éÙ©AAvP[VÌ¬»âATSUBAMEð\\¬·éCPUÆGPUÌ×ªUÌæ¤ÈHPC(High Performance Computing)Ì¤àißÄ¨èA^pN¿Ì§Ì\\¢\\ªvOAlphaFoldÉÂ¢ÄàvOÌüPÌpull requestðÁ½èàµÄ¢Ü·BÜ½AwàA¼åwAÌ¤AYÆEÆÌð¬ðÊ¶Ä­È¤º^cðsÁÄ¢Ü·B ¤ºÉÍAHåÌîñHwnogÒÌ¼ÉApwAL@¬Ì¤ºâòwÌogÒÈÇL¢obNOhðÁ½w¶ªúX¤®ðsÁÄ¢Ü·B»¡ðÁ½ûÍºÐA²A­¾³¢B WHAT'S NEW 2024/1/9 Ö¤ÌwmÁÛ¤Ìz®Ì½ßÌ¤º©wÍ1/12(àjÆ2/19ijÅ·(ÔÑÍnÌw¶ü¯wikiÅ²mFº³¢B)B·¸©¯äLpXJ31816ºÜÅ¨zµº³¢B±ÌúÈOÅÌ©wó]ÍA[©SwslackÌDMÅ²Aº³¢B 2023/10/26 CBIwï2023NåïAÖ¤CmPNÌàV³ñÌ­\\\"Study Improves Performance of Pocket Comparisons Using Machine Learning\"ªA Excellent Presentation AwardsðóÜµvOÏõ·ÌãòîÕENEh{¤ ÄÚ âæ¢æ¶©çÌÜóð¸«Üµ½B 2023/9/4 LLMnò`WÉ¨¢ÄAÖ¤D2Ìº³ñÆM1ÌéØNª»ê¼ê1ÊÆ3ÊÉüÜµÜµ½iÚ×Í±¿çjB 2023/3/4 îñwïæ85ñSåïÉ¨¢ÄéØh«³ñiB4jªup[gÅK»MCTSðp¢½de novoªq¶¬è@ÌJ­vÌ­\\ðs¢w¶§ãÜðóÜµÜµ½B 2023/1/9 Ö¤ÌwmÁÛ¤Ìz®Ì½ßÌ¤º©wÍ1/13(àjÆ2/20ij10:00-12:00, 14:00-16:00 Å·B·¸©¯äLpXJ31816ºÜÅ¨zµº³¢B±ÌúÈOÅÌ©wó]ÍA[©slackÌDMÅ²Aº³¢B 2022/10/28 CBIwï2022NåïAÖ¤CmPNÌ¬àV³ñÌ­\\\"An Enhanced Machine Learning Models for Predicting Retrosynthesis Accessibility\"ªA Excellent Presentation AwardsðóÜµvOÏõ·Ìkåw³ö ¬ nê æ¶©çÌÜóð¸«Üµ½B 2022/6/30 2022N317úÉ¡c¹l³ñiB4)ªîñwïnCptH[}XRs [eBO¤ïÅ­\\µ½u^pN¿§Ì\\¢\\ªVXeAlphaFoldÌTSUBAME3.0ãÅÌ¬»vÉæèAîñwï2022NxRs [^TCGXÌæ§ãÜðóÜµÜµ½B 2022/4/7 2021Nxîñwïæ69ñoCIîñw¤­\\ïÉ¨¯ébì å÷³ñiM2juCÓÌªqðo­_Æ·éOtx[XÌªqÅK»è@ÌJ­vÆºc ãÄ¾N³ñiM2ju@BwKðp¢½`¿ÌKhÊÌ`óðl¶µ½3³ `®Ì»¨Ì¶¬è@ÌJ­vÌxXgv[e[VÜóÜªèvµÜµ½B 2022/4/1 ¡NxàAæëµ­¨è¢\\µã°Ü·B 2022/3/3 îñwïæ84ñSåïÉ¨¢Äbìå÷³ñiM2jªu[w­»wKÉæéCÓÌªqðo­_Æµ½ªqÅK»è@ÌJ­vÌ­\\ðs¢w¶§ãÜðóÜµÜµ½B 2022/3/2 R{¤õªMªÅ éuV^RiECXÌBÉK{ÈyfðjQ·éyv`hlÅÍÈ¢VK»¨Qð­©vÉÂ¢ÄÌvX[Xðs¢Üµ½B_¶Í±¿çB 2021/4/3 Ö¤ºÉz®ªÜÁ½wEåw@Ìw¶³ñÅÖ¤ÌslackÉo^³êÄ¢È¢ûÍAå} ÜÅ²A­¾³¢B 2020/11/30 Ö­ay³öªoÏYÆÈÌßa2Nxuîñ»£iv£Âl\\²voÏYÆåbÜðóÜµÜµ½BHåvX[XÍ±¿çÅ·B Ê^FoÏYÆÈÌ@´cêåb­±¯i¶j©ç\\²óðö^³êéÖy³ö 2020/8/20 V^RiECXiSARS-CoV-2jÌCveA[[ÌECX¡»@\\jQÉdvÈt@[}RtHAÌfOÉ¬÷µÜµ½B_¶Í±¿çBvX[XÍ±¿çB 2020/4/1 Öy³öªÈwZpn¬¤@©çîñHw@Ézu·ÉÈèÜµ½B 2020/3/31 {útÅX}[gnò¤jbgªp~ÉÈèÜµ½B±êÜÅA½­ÌFlÌ²xðèÜµ½±ÆÉú­äçð\\µã°Ü·B 2020/3/3 úV· [§uø­ù¶òT¹@XpRÅìpðÍvÅÖ¤ºÌ¤ªæèã°çêÜµ½B 2020/3/1 V^RiECX¡ÃòTõðs¤½ßAR{ê÷ãtª¤õÆµÄ CµÜµ½B 2020/2/26 úoV·V· |^@gV^Riuïµ¢aC¾v@òJ­ÖAIp@´õgåðh°i3jhÅÖy³öÌ¤ªæèã°çêÜµ½B 2019/11/19 ÖªAHÆåw@VZpà¾ïÅunòÌêåÆÌÚðãÖ·éAIÌJ­Æ»ÌpvÆèµÄÁè2019-015086ÉÂ¢ÄA»ÌZpÌà¾ðs¢Üµ½B{ZpðnßARandom ForestÉæéSIEVE-Scoreâ3DCNNÌnòpÉ»¡Ì ééÆÌFlÍA[ÅÌ²Að¨Ò¿µÄ¨èÜ·B 2019/10/23 CmQNÌLi GenNªCBIwï2019NåïÅMªÅ­\\ðsÁ½\"Focused Library Generative Model for GPCR Family\"ªAExcellent PosterÜðóÜ¢½µÜµ½B 2019/10/13 M2iJ­jÌËcNðSÉJ­ªsíê½fB[v[jOÉæèfBViP~XgÌvisual inspectionðãÖ·é±ÆðÚIÉJ­ªsíê½VisINetÉÂ¢ÄAú{oÏV·©§Éuãòióâ AIÅIÊ ø¦AJ­RXg}§Ö@HåvÆ¢¤LªfÚ³êÜµ½B 2019/4/26 còiHÆÆ¤ºÆÌ¤¯¤ÉÂ¢ÄAS26úÉu`hnòASYJ­vHåÆcª¤¯¤_ñÆ¢¤LªfÚ³êÜµ½B 2019/4/22 M2(­\\)ÌËcNª¡N3Ìú{òwïæ139NïÅsÁ½ufB[v[jOðp¢½^pN¿ - Kh\\ªè@ÌJ­vÆ¢¤­\\ªAw¶DG­\\Üi|X^[­\\ÌjðóÜµÜµ½B696R¸è84èióÜ¦ 12.1%jªIÎê½»¤Å·B 2019/4/12 ucòiHÆÆAInòÌASYJ­ÉÖ·é¤¯¤ðJnvÆ¢¤[Xðs¢Üµ½B 2019/3/25 D3ÀöNªMªÌ_¶\"Improved Method of Structure-Based Virtual Screening via Interaction-Energy-Based Learning\"ªAAJ»wï_¶Journal of Chemical Information and ModelingÉfÚ³êASupplymentaly Cover ArtÉàIÎêÜµ½B 2019/3/15 îñwïæ18ñSåïÅM2ËcNÆM1¬R­ñªA»ê¼êu^pN¿[KhÉ¨¯éfB[v[jOðp¢½\\ªè@ÌJ­vuAugmented Realityðp¢½^pN¿Eòóâ»¨ÌO³\\¢Â»ÉæénòxVXeÌJ­vÆ¢¤^CgÅ­\\ðs¢AËcNªw¶§ãÜðóÜ¢½µÜµ½B 2018/12/5 D3ÀöNªXyC}h[hÅ12/3-6ÅJÃ³êÄ¢éIEEE International Conference on Bioinformatics and Biomedicine (BIBM)É¨¢ÄA\"CoDe-DTI:Collaborative Deep Learning based Drug Target Interaction Prediction\"Æ¢¤^CgÅuðs¢Üµ½B copyright (c) 2009-2023 Sekijima Lab. All rights reserved. design ev[g",
  "content_length": 7255,
  "method": "requests",
  "crawl_time": "2025-12-01 13:55:10"
}